InVivo Therapeutics (NASDAQ:NVIV) Share Price Crosses Above 200 Day Moving Average of $5.94

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIVGet Rating) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.94 and traded as high as $6.50. InVivo Therapeutics shares last traded at $5.92, with a volume of 70,934 shares.

Wall Street Analysts Forecast Growth

Separately, initiated coverage on InVivo Therapeutics in a report on Saturday. They issued a “sell” rating for the company.

InVivo Therapeutics Stock Up 7.4 %

The firm has a 50 day moving average price of $5.70 and a 200 day moving average price of $5.94. The stock has a market cap of $8.23 million, a P/E ratio of -0.77 and a beta of 1.05.

Hedge Funds Weigh In On InVivo Therapeutics

An institutional investor recently raised its position in InVivo Therapeutics stock. Renaissance Technologies LLC boosted its holdings in shares of InVivo Therapeutics Holdings Corp. (NASDAQ:NVIVGet Rating) by 152.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,300 shares of the biotechnology company’s stock after buying an additional 47,900 shares during the period. Renaissance Technologies LLC owned approximately 5.78% of InVivo Therapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 4.53% of the stock is owned by institutional investors and hedge funds.

About InVivo Therapeutics

(Get Rating)

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI.

Featured Articles

Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with's FREE daily email newsletter.